Ceftriaxone Dosing for CNS Infections

Standard Dosing Algorithm

The standard dosing algorithm for ceftriaxone in adults with bacterial meningitis and other CNS infections is 2 grams IV every 12 hours, with a total daily dose of 4 grams, as recommended by the Infectious Diseases Society of America 1, 3
For adult patients under 60 years, ceftriaxone 2g IV every 12 hours alone is recommended, while patients 60 years and older should have amoxicillin 2g IV every 4 hours added to the ceftriaxone regimen to cover Listeria monocytogenes, according to the American College of Physicians 1, 3
If penicillin-resistant pneumococci are suspected, vancomycin 15-20 mg/kg IV every 12 hours or rifampicin 600 mg IV/PO every 12 hours should be added to the ceftriaxone regimen, as suggested by the Centers for Disease Control and Prevention 1, 3

The treatment duration for meningococcal meningitis is 5 days if the patient has recovered, as recommended by the World Health Organization 1, 2, 4
For pneumococcal meningitis, the treatment duration is 10 days if the patient is stable by day 10, but may be extended to 14 days if the response is slower, according to the Infectious Diseases Society of America 1, 4
Haemophilus influenzae meningitis requires a treatment duration of 10 days, as recommended by the American Academy of Pediatrics 1, 4
Enterobacteriaceae (gram-negative bacilli) meningitis requires a treatment duration of 21 days, according to the Centers for Disease Control and Prevention 1, 4
Listeria monocytogenes meningitis requires a treatment duration of 21 days, with amoxicillin added to the ceftriaxone regimen, as recommended by the Infectious Diseases Society of America 1, 4

Twice-daily administration of ceftriaxone (every 12 hours) is essential to maintain adequate CSF concentrations throughout the entire dosing interval, as recommended by the American College of Physicians 1, 3
Current guidelines uniformly recommend twice-daily dosing for the first 24-48 hours at minimum to achieve rapid CSF sterilization, according to the Infectious Diseases Society of America 3